Labcorp Inc.
Rating
Updated: Sep 12, 2026Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Labcorp Holdings, Inc. offers vital diagnostic laboratory services, enabling medical professionals, healthcare facilities, pharmaceutical firms, scientific investigators, and patients to make well-inf...
Latest News
6 hours ago · fool.com
Why Labcorp Holdings Stock Dropped TodayMedicare and Medicaid have been overpaying Labcorp for years, says the government. Starting next year, they plan to cut reimbursement of lab testing by 15%.
7 days ago · seekingalpha.com
Labcorp Holdings Inc. (LH) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptLabcorp Holdings Inc. (LH) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
12 days ago · seekingalpha.com
Labcorp Holdings Inc. (LH) Analyst/Investor Day TranscriptLabcorp Holdings Inc. (LH) Analyst/Investor Day Transcript
12 days ago · benzinga.com
Labcorp Bets Big on AI, Specialty Testing to Drive Growth Through 2029Labcorp Holdings (NYSE:LH) on Thursday presented a comprehensive growth strategy and long-term financial forecast during its 2026 Investor Day.
12 days ago · prnewswire.com
Labcorp Highlights Strategic Priorities Driving Durable Growth and Shareholder Value at 2026 Investor DayReaffirms full-year 2026 guidance Provides long-term outlook through 2029, with compound annual revenue growth of 5% to 8% and compound annual adjusted earnings per share (EPS) growth of 8.5% to 11.5% Outlines strategic growth priorities driven by a differentiated platform powered by science, technology and global scale Presents long-term value creation framework driven by sustainable growth, strong cash flow generation and disciplined capital deployment BURLINGTON, N.C., Sept. 10, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today will host its 2026 Investor Day at 9 a.m.
13 days ago · prnewswire.com
Moonwalk Biosciences Announces $70 Million Series B: NYSE Content UpdateNYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Sept.
15 days ago · zacks.com
Why Labcorp Holdings (LH) is a Top Value Stock for the Long-TermWondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
20 days ago · zacks.com
Here's Why Labcorp Holdings (LH) is a Strong Momentum StockThe Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
28 days ago · zacks.com
Should You Continue to Hold Labcorp Stock in Your Portfolio?LH's specialty-testing expansion, strategic partnerships and buybacks support growth, while reimbursement and cost pressures pose risks.
29 days ago · prnewswire.com
Labcorp to Offer First FDA-Cleared Blood Test to Detect Alzheimer's Disease Pathology in Both Primary and Specialty Care SettingsElecsys® pTau-217 is the first and only FDA-cleared single-biomarker blood test to both rule in and rule out amyloid pathology across specialty and primary care settings Measures phosphorylated Tau 217 (pTau-217), an indicator of amyloid pathology and a hallmark of Alzheimer's disease Intended for individuals 55 and older with signs, symptoms or complaints of cognitive decline BURLINGTON, N.C., Aug. 24, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it will offer the Elecsys® pTau-217 test following clearance by the U.S. Food and Drug Administration (FDA).
Analyst Summary
Add to Watchlist
Select watchlists to add or remove LH